GlassScriptPhysician profile
Ashley Todd
NPI 1669228920
$2,788.89
in general payments reported to CMS, 2019-2025
21 companies · $203 in 2025
The $203 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,586 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,777 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,776.74 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $377.49 | 2024-2025 | Azstarys |
| Tris Pharma INC | $311.32 | 2024 | Dyanavel Xr, Quillichew Er, Quillivant |
| Teva Pharmaceuticals USA, INC. | $274.80 | 2024-2025 | Uzedy, Austedo Xr |
| Abbvie INC. | $264.63 | 2024 | |
| Ironshore Pharmaceuticals INC. | $176.81 | 2024 | |
| Lundbeck LLC | $173.91 | 2024 | Rexulti |
| Axsome Therapeutics, INC. | $168.05 | 2024-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $166.05 | 2024 | Caplyta |
| Neurocrine Biosciences, INC. | $151.07 | 2024 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $150.36 | 2024 | Cobenfy |
| Alkermes, INC. | $149.03 | 2024 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $96.07 | 2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $76.27 | 2024-2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $70.98 | 2024 | Trintellix |
| Harmony Biosciences LLC | $40.46 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $37.80 | 2024 | Xelstrym |
| Janssen Pharmaceuticals, INC | $29.64 | 2024 | Spravato |
| Bausch Health US, LLC | $21.05 | 2024 | Aplenzin |
| Idorsia Pharmaceuticals US INC | $18.29 | 2024 | Quviviq |
| Sage Therapeutics, LLC | $17.57 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.24 | 2024 | Rejoyn |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Todd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.